This draft guidance, when finalized, will represent the current thinking of the Food and Drug 
Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person 
and is not binding on FDA or the public. You can use an alternative approach if it satisfies the 
requirements of the applicable statutes and regulations. To discuss an alternative approach, contact 
the Office of Generic Drugs. 

 

Active Ingredient: Albuterol sulfate 

 

Dosage Form; Route: Tablet; oral 

 

Recommended Studies: Two studies 

 

1. Type of study: Fasting 


Design: Single-dose, two-way crossover in vivo 

Strength: EQ 4 mg base 

Subjects: Healthy males and females, general population 

Additional Comments: None 

 

 

 2. Type of study: Fed 

Design: Single-dose, two-way crossover in vivo 

Strength: EQ 4 mg base 

Subjects: Healthy males and females, general population 

Additional Comments: None 

 

 

Analytes to measure (in appropriate biological fluid): Albuterol in plasma 

 

Bioequivalence based on (90% CI): Albuterol 

 

Waiver request of in vivo testing: EQ 2 mg base strength based on (i) acceptable 
bioequivalence studies on the EQ 4 mg base strength, (ii) acceptable dissolution testing across all 
the strengths, and (iii) proportional similarity in the formulations across all the strengths. 

 

Dissolution test method and sampling times: 

The dissolution information for this drug product can be found on the FDA-Recommended 
Dissolution Methods website, available to the public at the following location: 
http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please conduct comparative 
dissolution testing on 12 dosage units each of all strengths of the test and reference products. 
Specifications will be determined upon review of the abbreviated new drug application 
(ANDA). 

 


